$GOVX
GeoVax Labs, Inc. Stock $govx

$govx Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000143774922005677 Filed on March 09, 2022

Income Statement

Concept	2021 Q1	2021	2020 Q4
Revenue	$110.4K	$385.5K	$250.0K
YoY Change	-84.58%	-78.86%	-7.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.070M	$3.577M	$830.0K
YoY Change	114.0%	62.6%	97.62%
% of Gross Profit
Research & Development	$602.8K	$15.55M	$760.0K
YoY Change	-25.48%	536.3%	72.73%
% of Gross Profit
Depreciation & Amortization	$4.517K	$38.52K	$20.00K
YoY Change	354.43%	95.98%
% of Gross Profit
Operating Expenses	$1.674M	$19.13M	$1.590M
YoY Change	27.7%	312.27%	84.88%
Operating Profit	-$1.564M	-$18.75M
YoY Change	162.74%	565.5%
Interest Expense	$755.00	$1.286K	$0.00
YoY Change	-33.89%	-99.1%
% of Operating Profit
Other Income/Expense, Net	$1.298K	$175.5K
YoY Change	-432.82%	-224.25%
Pretax Income	-$1.560M	-$18.57M	-$1.340M
YoY Change	160.0%	527.38%	127.12%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.563M	-$18.57M	-$1.340M
YoY Change	162.35%	527.79%	127.12%
Net Earnings / Revenue	-1415.34%	-4817.19%	-536.0%
Basic Earnings Per Share	-$0.29	-$3.04
Diluted Earnings Per Share	-$292.7K	-$3.044M	-$349.9K
COMMON SHARES
Basic Shares Outstanding	5.332M	6.100M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.84M	$11.42M	$9.880M
YoY Change	9372.73%	15.63%	3428.57%
Cash & Equivalents	$20.84M	$11.42M	$9.884M
Short-Term Investments
Other Short-Term Assets	$120.0K	$156.2K	$170.0K
YoY Change	71.43%	-8.09%	70.0%
Inventory
Prepaid Expenses
Receivables	$0.00	$49.01K	$180.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.96M	$11.63M	$10.24M
YoY Change	2487.13%	13.57%	2188.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$143.2K	$156.9K	$147.7K
YoY Change	1390.05%	4.63%	1292.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$11.01K	$10.00K
YoY Change	0.0%	10.1%	0.0%
Total Long-Term Assets	$154.2K	$167.9K	$158.8K
YoY Change	647.91%	11.96%	634.41%
TOTAL ASSETS
Total Short-Term Assets	$20.96M	$11.63M	$10.24M
Total Long-Term Assets	$154.2K	$167.9K	$158.8K
Total Assets	$21.12M	$11.80M	$10.39M
YoY Change	2441.48%	13.54%	2116.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$232.5K	$2.058M	$267.7K
YoY Change	-68.62%	662.05%	75.37%
Accrued Expenses	$36.62K	$3.378M	$359.3K
YoY Change	-98.09%	838.29%	-80.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$180.0K	$0.00	$180.0K
YoY Change	1700.0%	-100.0%	1700.0%
Total Short-Term Liabilities	$451.9K	$5.435M	$810.3K
YoY Change	-83.07%	571.03%	-59.81%
LONG-TERM LIABILITIES
Long-Term Debt	$10.00K	$0.00	$10.00K
YoY Change	-50.0%	-100.0%	-66.67%
Other Long-Term Liabilities		$2.000M
YoY Change
Total Long-Term Liabilities	$10.00K	$2.000M	$10.00K
YoY Change	-50.0%	19900.0%	-66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$451.9K	$5.435M	$810.3K
Total Long-Term Liabilities	$10.00K	$2.000M	$10.00K
Total Liabilities	$464.1K	$7.435M	$825.0K
YoY Change	-82.78%	795.83%	-59.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.37M		-$45.81M
YoY Change	9.04%		6.9%
Common Stock	$67.94M		$55.30M
YoY Change	64.9%		40.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.65M	$4.362M	$9.569M
YoY Change
Total Liabilities & Shareholders Equity	$21.12M	$11.80M	$10.39M
YoY Change	2441.48%	13.54%	2116.75%

Cashflow Statement

Concept	2021 Q1	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$1.563M	-$18.57M	-$1.340M
YoY Change	162.35%	527.79%	127.12%
Depreciation, Depletion And Amortization	$4.517K	$38.52K	$20.00K
YoY Change	354.43%	95.98%
Cash From Operating Activities	-$1.621M	-$11.20M	-$1.540M
YoY Change	352.02%	307.06%	450.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$47.72K	-$160.0K
YoY Change		-69.57%	1500.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$47.72K	-$160.0K
YoY Change		-69.57%	1500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$9.400M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$12.58M	$12.78M	0.000
YoY Change	4134.47%	2.21%
NET CHANGE
Cash From Operating Activities	-$1.621M	-$11.20M	-1.540M
Cash From Investing Activities	$0.00	-$47.72K	-160.0K
Cash From Financing Activities	$12.58M	$12.78M	0.000
Net Change In Cash	$10.96M	$1.540M	-1.700M
YoY Change	-17909.64%	-83.96%	486.21%
FREE CASH FLOW
Cash From Operating Activities	-$1.621M	-$11.20M	-$1.540M
Capital Expenditures	$0.00	$47.72K	-$160.0K
Free Cash Flow	-$1.621M	-$11.24M	-$1.380M
YoY Change	352.02%	286.75%	411.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6381541
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6381541
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3834095
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3834095
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11423870	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9883796	USD
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	49006	USD
CY2020Q4	us-gaap	Grants Receivable GrantsReceivable	182663	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	10235148	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	716790
CY2021Q4	us-gaap	Liabilities Liabilities	7435360	USD
CY2020Q4	us-gaap	Liabilities Liabilities	825047	USD
CY2020	govx	Stock Issued During Period Shares Cancellation Of Accrued Compensation StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation	300001
CY2020	govx	Deferred Compensation Liability Conversion To Equity Amount DeferredCompensationLiabilityConversionToEquityAmount	1500000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	156240	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	168689	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.14
CY2021Q4	us-gaap	Assets Current AssetsCurrent	11629116	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	76095	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156938	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	147741	USD
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	11010	USD
CY2020Q4	us-gaap	Deposits Assets DepositsAssets	11010	USD
CY2021Q4	us-gaap	Assets Assets	11797064	USD
CY2020Q4	us-gaap	Assets Assets	10393899	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2057534	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	267702	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3377826	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	359281	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	183326	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5435360	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	810309	USD
CY2021Q4	govx	Accrued Expenses Noncurrent AccruedExpensesNoncurrent	2000000	USD
CY2020Q4	govx	Accrued Expenses Noncurrent AccruedExpensesNoncurrent	0	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14738	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6382	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3834	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	68731220	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55294504	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64375898	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45805581	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4361704	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	9568852	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11797064	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10393899	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	385501	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1823658	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15554171	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2444459	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3577153	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2196014	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	19131324	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	4640473	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-18745823	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-2816815	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	4736	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	2271	USD
CY2021	us-gaap	Interest Expense InterestExpense	1286	USD
CY2020	us-gaap	Interest Expense InterestExpense	143524	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	172056	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	175506	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-141253	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-18570317	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2958068	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.04
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-1574556	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	300000	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6099933
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1383829
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12507816	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2958068	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38521	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12784212	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19656	USD
CY2020	govx	Stock Issued During Period Value Debenture Conversion StockIssuedDuringPeriodValueDebentureConversion	569517	USD
CY2020	govx	Stock Issued During Period Value Cancellation Of Accrued Compensation StockIssuedDuringPeriodValueCancellationOfAccruedCompensation	1500000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11158496	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	457833	USD
CY2020	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	2500	USD
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	94400	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18730	USD
CY2020	govx	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2958068	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	9568852	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9408920	USD
CY2021	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	3404156	USD
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	71841	USD
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	269427	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-18570317	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4361704	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-18570317	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	124185	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	369987	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	64463	USD
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	209825	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	172056	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	USD
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-133657	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	114060	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16270	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	24702	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6810233	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	137956	USD
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	7373897	USD
CY2020	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	207498	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11196420	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2750570	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47718	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	156791	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47718	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-156791	USD
CY2021	govx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	9408920	USD
CY2020	govx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	11158496	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3404156	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2500	USD
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	300000	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	170200	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	888500	USD
CY2021	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	1000	USD
CY2020	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	-0	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	27864	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	11880	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9883796	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	283341	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11423870	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1540074	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9600455	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9883796	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Description of Business and Recent Developments</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials in COVID-<em style="font: inherit;">19</em> and head and neck cancer. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for solid tumors. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GEO-<em style="font: inherit;">CM04S1</em> License</i> -- In <em style="font: inherit;"> November 2021, </em>GeoVax entered into a license agreement with City of Hope (the “COH License”), granting GeoVax exclusive rights to further develop and commercialize GEO-<em style="font: inherit;">CM04S1</em> (formerly referred to as <em style="font: inherit;">COH04S1</em>). GEO-<em style="font: inherit;">CM04S1,</em> a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing Spike and Nucleocapsid antigens of the SARS-CoV-<em style="font: inherit;">2</em> virus, was initially developed at COH for immunocompromised patients.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GEO-<em style="font: inherit;">CM04S1</em> is being studied in an ongoing Phase <em style="font: inherit;">2</em> clinical trial to evaluate its safety and immunogenicity, compared to the Pfizer mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-<em style="font: inherit;">CM04S1</em> is the only COVID-<em style="font: inherit;">19</em> vaccine that includes both SARS-CoV-<em style="font: inherit;">2</em> spike and nucleocapsid proteins to advance to a Phase <em style="font: inherit;">2</em> trial in cancer patients. Such vaccines also tend to produce an immune response quickly – in less than <em style="font: inherit;">14</em> days – with only mild side effects. The trial is also the <em style="font: inherit;">first</em> to compare an investigational multi-antigenic COVID-<em style="font: inherit;">19</em> vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-<em style="font: inherit;">19</em> vaccines.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> December 2021, </em>patient enrollment began for the Phase <em style="font: inherit;">2</em> portion of a Phase <em style="font: inherit;">1/2</em> trial of GEO-<em style="font: inherit;">CM04S1,</em> to study its use as a universal booster vaccine to current FDA-approved vaccines. GeoVax believes that the GEO-<em style="font: inherit;">CM04S1</em> vaccine, when administered as a heterologous booster, will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines such as those developed by Moderna or Pfizer, which are directed only toward SARS-CoV-<em style="font: inherit;">2</em> Spike protein. The <em style="font: inherit;">COH04S1</em> vaccine’s MVA backbone <em style="font: inherit;"> may </em>be more effective at inducing COVID-<em style="font: inherit;">19</em> immunity since MVA strongly induces T cell responses even in a background of immunosuppression. In addition, GEO-<em style="font: inherit;">CM04S1</em> targeting of both Spike and Nucleocapsid antigens, <em style="font: inherit;"> may </em>offer greater protection against the significant sequence variation observed with the Spike antigen.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Gedeptin</i>®<i> License</i> -- In <em style="font: inherit;"> September 2021, </em>GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc. (the “PNP License), whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin®, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase <em style="font: inherit;">1/2</em> clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and <em style="font: inherit;">no</em> curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax’s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but <em style="font: inherit;">not</em> limited to, cancers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p>
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	659441	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	550221	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	511700	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156938	USD
CY2020Q3	govx	Proceeds From Issuance Or Sale Of Equity Gross ProceedsFromIssuanceOrSaleOfEquityGross	12800000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	147741	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38521	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	213831
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1001948
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p>
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	707159	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19656	USD
CY2021Q4	govx	Accrued License Fees Current AccruedLicenseFeesCurrent	3000000	USD
CY2020Q4	govx	Accrued License Fees Current AccruedLicenseFeesCurrent	0	USD
CY2021Q4	govx	Accrued License Fees Noncurrent AccruedLicenseFeesNoncurrent	2000000	USD
CY2020Q4	govx	Accrued License Fees Noncurrent AccruedLicenseFeesNoncurrent	0	USD
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	269000	USD
CY2020Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	279696	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	108826	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	79585	USD
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	5377826	USD
CY2020Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	359281	USD
CY2018Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	50000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1286	USD
CY2020	us-gaap	Interest Expense InterestExpense	143524	USD
CY2021Q4	govx	Licensing Agreement Future Minimum Payments Receivable Current LicensingAgreementFutureMinimumPaymentsReceivableCurrent	174000	USD
CY2021Q4	govx	Licensing Agreement Future Minimum Payments Receivable In Two Years LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears	128000	USD
CY2021Q4	govx	Licensing Agreement Future Minimum Payments Receivable In Three Years LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears	128000	USD
CY2021Q4	govx	Licensing Agreement Future Minimum Payments Receivable In Four Years LicensingAgreementFutureMinimumPaymentsReceivableInFourYears	28000	USD
CY2021Q4	govx	Licensing Agreement Future Minimum Payments Receivable In Five Years LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears	28000	USD
CY2021Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	407000	USD
CY2020Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	177626
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1644000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0069	pure
CY2020Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11200000	USD
CY2020Q3	govx	Deferred Compensation Liability Conversion To Equity Amount DeferredCompensationLiabilityConversionToEquityAmount	1500000	USD
CY2020Q3	govx	Deferred Compensation Liability Conversion To Equity Conversion Price DeferredCompensationLiabilityConversionToEquityConversionPrice	5.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2020Q3	govx	Stock Issued During Period Shares Cancellation Of Accrued Compensation StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation	300001
CY2020Q3	govx	Number Of Common Stock Securities Called By Each Unit NumberOfCommonStockSecuritiesCalledByEachUnit	1
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10300000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9400000	USD
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	13707
CY2020	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	26581
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0143	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8480	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3816	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	602000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.79
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	360300
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.82
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	962300
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M21D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	499660	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	200661
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.79
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y11M4D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	166549	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.87
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.12
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2816631
CY2021Q4	govx	Prepaid Expense Value Of Stock Issued For Services During Period PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod	19947	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	36980	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	27511	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18449694	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14737240	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1566293	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1189110	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	129475	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4870	USD
CY2021Q4	govx	Deferred Tax Assets Accrued Salaries DeferredTaxAssetsAccruedSalaries	69940	USD
CY2020Q4	govx	Deferred Tax Assets Accrued Salaries DeferredTaxAssetsAccruedSalaries	72721	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	20215402	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	16003941	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	30945	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	28274	USD
CY2021Q4	govx	Deferred Tax Assets Before Valuation Allowance Net DeferredTaxAssetsBeforeValuationAllowanceNet	20184457	USD
CY2020Q4	govx	Deferred Tax Assets Before Valuation Allowance Net DeferredTaxAssetsBeforeValuationAllowanceNet	15975667	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20184457	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15975667	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-0	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3899767	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-621194	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	65	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	377183	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	66574	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4276950	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	687703	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2021Q4	govx	Unused Grant Funds UnusedGrantFunds	81526	USD

Files In Submission

Name	View Source	Status
0001437749-22-005677-index-headers.html	Edgar Link	pending
0001437749-22-005677-index.html	Edgar Link	pending
0001437749-22-005677.txt	Edgar Link	pending
0001437749-22-005677-xbrl.zip	Edgar Link	pending
ex_339970.htm	Edgar Link	pending
ex_339971.htm	Edgar Link	pending
ex_339972.htm	Edgar Link	pending
ex_343680.htm	Edgar Link	pending
ex_344528.htm	Edgar Link	pending
ex_344529.htm	Edgar Link	pending
ex_344530.htm	Edgar Link	pending
ex_344531.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
geovax.jpg	Edgar Link	pending
govx-20211231.xsd	Edgar Link	pending
govx-20211231_cal.xml	Edgar Link	unprocessable
govx-20211231_def.xml	Edgar Link	unprocessable
govx-20211231_lab.xml	Edgar Link	unprocessable
govx-20211231_pre.xml	Edgar Link	unprocessable
govx20211231_10k.htm	Edgar Link	pending
govx20211231_10k_htm.xml	Edgar Link	completed
img01.jpg	Edgar Link	pending
img02.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOVX
GeoVax Labs, Inc. Stock $govx

2021 Q1 Form 10-K Financial Statement

#000143774922005677 Filed on March 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOVX GeoVax Labs, Inc. Stock $govx

2021 Q1 Form 10-K Financial Statement

#000143774922005677 Filed on March 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOVX
GeoVax Labs, Inc. Stock $govx